Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NASDAQ:LEGN NASDAQ:VKTX NASDAQ:VOR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$24.44+2.3%$20.38$8.88▼$25.00$4.05B1.062.59 million shs5.07 million shsLEGNLegend Biotech$22.22-5.6%$28.87$16.24▼$44.17$4.13B0.341.84 million shs1.69 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.04B0.662.27 million shs1.84 million shsVORVor Biopharma$19.26+1.5%$16.26$6.50▼$53.00$1.04B1.691.74 million shs638,990 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics0.00%+2.95%+18.58%+33.84%+160.55%LEGNLegend Biotech0.00%-0.18%-21.84%-7.03%-49.86%VKTXViking Therapeutics0.00%-6.18%-5.95%+6.23%+4.16%VORVor Biopharma0.00%+6.47%+29.00%+39.46%-53.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$24.44+2.3%$20.38$8.88▼$25.00$4.05B1.062.59 million shs5.07 million shsLEGNLegend Biotech$22.22-5.6%$28.87$16.24▼$44.17$4.13B0.341.84 million shs1.69 million shsVKTXViking Therapeutics$34.79-1.7%$33.79$22.96▼$43.15$4.04B0.662.27 million shs1.84 million shsVORVor Biopharma$19.26+1.5%$16.26$6.50▼$53.00$1.04B1.691.74 million shs638,990 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics0.00%+2.95%+18.58%+33.84%+160.55%LEGNLegend Biotech0.00%-0.18%-21.84%-7.03%-49.86%VKTXViking Therapeutics0.00%-6.18%-5.95%+6.23%+4.16%VORVor Biopharma0.00%+6.47%+29.00%+39.46%-53.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 2.87Moderate Buy$34.1739.80% UpsideLEGNLegend Biotech 2.50Moderate Buy$55.38149.26% UpsideVKTXViking Therapeutics 2.67Moderate Buy$97.00178.82% UpsideVORVor Biopharma 2.82Moderate Buy$42.25119.37% UpsideCurrent Analyst Ratings BreakdownLatest VOR, LEGN, DYN, and VKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026LEGNLegend Biotech UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$49.00 ➝ $28.007/23/2026DYNDyne Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight7/20/2026VKTXViking Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell7/17/2026DYNDyne Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/17/2026VKTXViking Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/16/2026LEGNLegend Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy7/13/2026LEGNLegend Biotech JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$35.007/10/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026LEGNLegend Biotech Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$64.00 ➝ $63.006/30/2026VORVor Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/26/2026DYNDyne Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/ALEGNLegend Biotech$1.03B4.01N/AN/A$5.43 per share4.09VKTXViking TherapeuticsN/AN/AN/AN/A$5.65 per shareN/AVORVor BiopharmaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A14.24N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)VKTXViking Therapeutics-$359.64M-$4.14N/AN/AN/AN/A-71.31%-65.35%7/29/2026 (Estimated)VORVor BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AN/ALatest VOR, LEGN, DYN, and VKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/10/2026Q2 2026LEGNLegend Biotech$0.0554N/AN/AN/A$356.01 millionN/A7/29/2026Q2 2026VKTXViking Therapeutics-$1.21N/AN/AN/AN/AN/A7/27/2026Q2 2026DYNDyne Therapeutics-$0.74N/AN/AN/AN/AN/A5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A4/30/2026Q1 2026VKTXViking Therapeutics-$1.01-$1.37-$0.36-$1.37N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/AVKTXViking TherapeuticsN/AN/AN/AN/AN/AVORVor BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1719.9219.92LEGNLegend BiotechN/A2.132.05VKTXViking TherapeuticsN/A5.725.72VORVor BiopharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%LEGNLegend Biotech70.89%VKTXViking Therapeutics76.03%VORVor Biopharma97.29%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics9.46%LEGNLegend Biotech0.02%VKTXViking Therapeutics5.30%VORVor Biopharma0.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100165.53 million149.87 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableVKTXViking Therapeutics20116.11 million109.95 millionOptionableVORVor Biopharma14054.19 million54.04 millionN/AVOR, LEGN, DYN, and VKTX HeadlinesRecent News About These CompaniesVor Biopharma (NASDAQ:VOR) Stock Price Up 12% - What's Next?July 21, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Shares Down 5% - Here's WhyJuly 20, 2026 | marketbeat.comVor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from AnalystsJuly 15, 2026 | americanbankingnews.comVor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by AnalystsJuly 15, 2026 | marketbeat.comVor Biopharma (NASDAQ:VOR) Stock Price Down 6.2% - What's Next?July 13, 2026 | marketbeat.comVor Biopharma: Vor Bio Appoints David Zaccardelli to Board of DirectorsJuly 8, 2026 | finanznachrichten.deVor Bio Appoints David Zaccardelli to Board of DirectorsJuly 7, 2026 | globenewswire.comVor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market RealizesJuly 7, 2026 | seekingalpha.comVor Biopharma Stock Short Interest Report | NASDAQ:VOR | BenzingaJuly 3, 2026 | benzinga.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 2, 2026 | globenewswire.comWhy Vor Biopharma (VOR) Is Up 24.5% After Broad FTSE Russell Index Inclusion And What's NextJune 30, 2026 | finance.yahoo.comVor Biopharma: Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | finanznachrichten.deTelitacicept Receives NMPA Approval for the Treatment of Sjögren's Disease in ChinaJune 8, 2026 | globenewswire.comTelitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in ChinaJune 8, 2026 | globenewswire.comVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 1, 2026 | globenewswire.comVor Bio to Participate in the 2026 Jefferies Global Healthcare ConferenceMay 28, 2026 | globenewswire.comWe're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash WiselyMay 15, 2026 | finance.yahoo.comAnalysts Are Bullish on These Healthcare Stocks: Protara Therapeutics (TARA), Vor Biopharma (VOR)May 14, 2026 | theglobeandmail.comVor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of MedicineMay 14, 2026 | globenewswire.comVor Biopharma: Vor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | finanznachrichten.deVor Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Has Real Value—But These 3 Stocks Have Better Odds Right NowBy Bridget Bennett | June 28, 2026Doug Casey Calls AI a Super Bubble, Bets on Energy, Gold Miners and GrainsBy Bridget Bennett | July 6, 2026Why Flywire and Airbnb Could Be Quiet Winners of a CeasefireBy Nathan Reiff | July 4, 2026These 3 Cash-Flow Stocks Give Investors More Than Just Growth PotentialBy Nathan Reiff | July 8, 2026Forging Profits: The Executive Order Sparking AluminumBy Jeffrey Neal Johnson | July 23, 2026VOR, LEGN, DYN, and VKTX Company DescriptionsDyne Therapeutics NASDAQ:DYN$24.44 +0.55 (+2.30%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$24.42 -0.02 (-0.08%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Legend Biotech NASDAQ:LEGN$22.22 -1.31 (-5.57%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$22.37 +0.15 (+0.66%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Viking Therapeutics NASDAQ:VKTX$34.79 -0.60 (-1.70%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$35.06 +0.27 (+0.76%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.Vor Biopharma NASDAQ:VOR$19.26 +0.28 (+1.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$19.27 +0.01 (+0.05%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
